Epizyme Inc (EPZM)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139

Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Srl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate.

Data based on most recent fiscal year report
Market Cap1.174 Billion Shares Outstanding69.28 Million Avg Volume857.003 Thousand
1-Yr BETA vs S&P TR1.989 Current Ratio11.59 Quick Ratio11.59
View SEC Filings from EPZM instead.

View recent insider trading info

Funds Holding EPZM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EPZM BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MOTT DAVID M

  • Director
  • 10% Owner
0 2020-01-02 7

ROS MATTHEW

  • Director
0 2020-01-02 2

CONROY KEVIN T

  • Director
6,192 2019-12-31 4

BARRIS PETER J

  • Director
849,527 2019-12-26 0

SANDELL SCOTT D

  • 10% Owner
2,052,454 2019-12-24 0

BASKETT FOREST

  • 10% Owner
2,052,454 2019-12-24 0

ALLEN ANDREW R

  • Director
0 2019-12-19 1

KERINS PATRICK J

  • 10% Owner
9,569,451 2019-12-09 0

AGARWAL SHEFALI CHIEF MEDICAL OFFICER

  • Officer
58,276 2019-12-02 5

RHODES JASON P

  • Director
4,934,687 2019-11-18 0

POPS RICHARD F DIRECTOR AND CEO, ALKERMES PLC

  • Officer
  • Director
716,433 2019-11-14 1

LEGORRETA PABLO G.

RP MANAGEMENT, LLC

RPI FINANCE TRUST

  • Director
6,666,667 2019-11-06 2

LEGORRETA PABLO G.

  • Director
0 2019-11-06 2

GIORDANO MICHAEL F

  • Director
0 2019-10-30 1

SEIDENBERG BETH C

  • Director
17,698,819 2019-10-29 2

BOGLE GRANT C.

  • Director
0 2019-09-02 2

RICHON VICTORIA

  • Director
0 2019-09-02 2

TOMBESI PAOLO CHIEF FINANCIAL OFFICER

  • Officer
0 2019-08-19 2

GOULD ROBERT J SEE REMARKS

  • Officer
  • Director
  • 10% Owner
0 2019-07-18 0

BATE KENNETH

  • Director
0 2019-07-18 1

BAZEMORE ROBERT B

  • Director
0 2019-06-25 2

BEAULIEU JOSEPH CORPORATE CONTROLLER

  • Officer
497 2019-06-12 2

GOLDFISCHER CARL

  • Director
0 2019-05-31 1

BARRETT M JAMES

  • Director
0 2019-05-30 0

NEW ENTERPRISE ASSOCIATES 13 LP

NEA PARTNERS 13, LIMITED PARTNERSHIP

NEA 13 GP, LTD

  • 10% Owner
0 2019-01-22 0

VISWANATHAN RAVI

  • 10% Owner
5,000,000 2018-10-17 0

GRAF SUSAN E CHIEF BUSINESS OFFICER

  • Officer
0 2018-02-09 0

FLEMING SUZANNE SVP

  • Officer
0 2018-02-09 0

NEA PARTNERS 13, LIMITED PARTNERSHIP

NEA 13 GP, LTD

  • 10% Owner
No longer subject to file 2017-11-06 0

NEW ENTERPRISE ASSOCIATES 13 LP

  • 10% Owner
No longer subject to file 2017-11-06 0

HO PETER TAI-CHING CHIEF DEVELOPMENT OFFICER

  • Officer
10,123 2017-10-24 0

SINGER ANDREW E. EVP & CFO

  • Officer
45,446 2017-08-09 0

COPELAND ROBERT A PRESIDENT OF RESEARCH AND CSO

  • Officer
31,538 2017-06-06 0

KOLLURI KRISHNA KITTU

  • 10% Owner
5,215,128 2016-12-19 0

WELLER HARRY R

  • 10% Owner
3,490,073 2016-10-31 0

BAY CITY CAPITAL LLC

BAY CITY CAPITAL FUND V, L.P.

BAY CITY CAPITAL FUND V CO-INVESTMENT FUND, L.P.

BAY CITY CAPITAL MANAGEMENT V LLC

  • 10% Owner
77,245,201 2016-07-29 0

DRANT RYAN D

  • 10% Owner
7,489,485 2015-06-05 0

GARBACZ STEPHEN PRINCIPAL ACCOUNTING OFFICER

  • Officer
13,073 2014-11-03 0

HEDRICK ERIC CHIEF MEDICAL OFFICER

  • Officer
429 2014-10-15 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

MOTT DAVID M - Director

2019-12-31 A 952 $24.60 a 19,070 4,444,387.00 direct

CONROY KEVIN T - Director

2019-12-31 A 452 $24.60 a 6,192 6,192.00 direct

AGARWAL SHEFALI - Officer CHIEF MEDICAL OFFICER

2019-12-02 A 22,577 a 58,276 58,276.00 direct

AGARWAL SHEFALI - Officer CHIEF MEDICAL OFFICER

2019-12-02 A 34,978 a 34,978 58,276.00 direct

AGARWAL SHEFALI - Officer CHIEF MEDICAL OFFICER

2019-12-02 A 22,577 a 58,276 58,276.00 direct

AGARWAL SHEFALI - Officer CHIEF MEDICAL OFFICER

2019-12-02 A 34,978 a 34,978 58,276.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments